Breakthrough Opioid Use Disorder (OUD) Asset Sale
Final LOI Due
TAEUS is managing the complete 100% asset divestiture of the Computerized Oral Prescription Administration System (COPA™) on behalf of Berkshire Biomedical Corporation. Designed to revolutionize treatment in sensitive areas like Opioid Use Disorder (OUD) and controlled drug administration, COPA™ represents a turnkey opportunity to acquire a fully validated, highly secure digital health platform.
A First-of-Its-Kind Dual-Biometric System
The COPA™ platform is a handheld device integrating dual-biometric authorization—requiring both fingerprint and dentition confirmation—paired with a cellular data transmission module and a proprietary, HIPAA-compliant Database Management System (DBMS).
De-Risked Tech & High-Value Asset Package
- $20M+ Invested: Over $20 million has been invested to date in hardware, software, and clinical development.
- Federal Support & Regulatory Progress: Supported by $2M+ in NIH and NIDA research grants, with a De Novo application previously entering formal FDA review.
- Turnkey Portfolio: Includes 36 global patents across four families, complete engineering files, firmware, and prototypes. Learn more about the technology at Berkshire Biomedical.
Final Letters of Interest Due
Contact your TAEUS representative today
With 7 multinational corporations actively evaluating this opportunity, time is running out to enter the process before it closes. Current ownership is structured to facilitate an efficient, streamlined due diligence process for a complete asset sale, technology spin-in, or outright IP assignment.
